Person: DOLAR, MAHMUT ENVER
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
DOLAR
First Name
MAHMUT ENVER
Name
5 results
Search Results
Now showing 1 - 5 of 5
Publication The expression and relationship of adipo R1/R2 in gastric intestinal metaplasia(Wolters Kluwer Medknow Publications, 2021-04-01) Ayyildiz, T.; Erturk, B.; Dolar, E.; DOLAR, MAHMUT ENVER; Ugras, N.; UĞRAŞ, NESRİN; Dizdar, O. S.; Adim, S. B.; Yerci, O.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Gastroentoloji Anabilim Dalı.; D-6213-2013; AAG-9177-2021Background: Adiponectin (ApN) is a 244-amino acid protein mainly secreted from the adipose tissue and involved in various physiological functions. ApN exerts its metabolic effects by binding to two major receptors: adiponectin receptor-1 (Adipo-R1) and adiponectin receptor-2 (Adipo-R2). Recent studies have reported ApN's involvement in the progression of cancer. However, there are no studies evaluating the relationship between Adipo-R1/R2 expression and gastric intestinal metaplasia (IM), which is a predisposing factor in gastric cancer (GC) development, and Helicobacter pylori H. pylori infection. Aims: In this study we aimed to investigate the relationship between the Adipo-R1/-R2 expression and H. pylori infection in patients with GC and gastric IM. Materials and Methods: Forty patients that underwent gastric resection and 56 patients that developed gastric IM were included in the study. The Adipo-R1/-R2 expression and the presence of H. pylori were examined immunohistochemically. The univariate analyses showed that the expression of Adipo-R1/-R2 in GC patients was significantly lower compared to both complete metaplasia (CM) and incomplete metaplasia (ICM) patients (p <0.0001 for both). Results: According to multiple multinomial logistic regression analysis, Adipo-R1/-R2 expression in the CM group was significantly higher than in the GC group (p = 0.05, p = 0.014, respectively). Moreover, Adipo-R1/-R2 expression was significantly higher in ICM group compared to the GC group (p=0.012, p=0.045, respectively). However, in both analyses no significant difference was determined in terms of H. pylori positivity between the groups.Conclusion: The resulting data suggests that ApN plays a role in GC processes via Adipo-R1/-R2 receptors.Publication Mean platelet volume is an important predictor of hepatitis c but not hepatitis b liver damage(Wolters Kluwer Medknow Publications, 2015-09-01) Eminler, Ahmet Tarık; Uslan, Mustafa Ihsan; Ayyıldız, Talat; Irak, Kader; Kıyıcı, Murat; KIYICI, MURAT; Gürel, Selim; GÜREL, SELİM; Dolar, Enver; DOLAR, MAHMUT ENVER; Gülten, Macit; GÜLTEN, MACİT; Nak, Selim Giray; NAK, SELİM GİRAY; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.; 0000-0002-0019-3207; 0000-0002-3208-6211; ABF-1568-2021; HLH-8209-2023; AAI-4213-2021; AAG-9177-2021Background: The mean platelet volume (MPV) is the most commonly used measure of platelet size and is a potential marker of platelet reactivity. In this study, we aimed to explore the relationship between hepatic histopathology in viral hepatitis and MPV levels, which are associated with platelet count and activity. Materials and Methods: We performed a retrospective case-control study of baseline histological and clinical parameters in chronic hepatitis B and C patients in our tertiary reference center between January 2005 and January 2011. Two hundred and five chronic hepatitis B patients and 133 chronic hepatitis C patients who underwent liver biopsy were included in the study. The patients were divided into two groups: Chronic hepatitis B and chronic hepatitis C and were additionally divided into groups of two according to histological activity index (HAI) and fibrosis scores obtained by liver biopsy results (according to the Ishak scoring system). The clinical characteristics of chronic viral hepatitis patients, including demographics, laboratory (especially MPV), and liver biopsy findings, were reviewed. Results: One hundred and forty-three patients were male (69.1%), and the mean age was 41.9 +/- 12.75 with an age range of 18-71 years in hepatitis B patients. In the classification made according to HAI, 181 patients were in the low activity group (88.3%) and 24 in the high activity group (11.7%). In the evaluation made according to fibrosis score, 169 patients were found to have early fibrosis (82.4%) and 36 were found to have advanced fibrosis (17.6%). In patients with hepatitis B, there was no statistically significant difference in terms of their MPV values between the two groups, separated according to their degree of activity and fibrosis. Sixty-three patients were male (47.3%), and the mean age was 50.03 +/- 12.75 with an age range of 19-75 years. In the classification made according to HAI, 109 patients were in low activity group (81.9%) and 24 in high activity group (18.1%). In the evaluation made according to fibrosis score, 101 patients were found to have early fibrosis (75.9%) and 32 have advanced fibrosis (24.1%). There was a statistically significant difference between the activity and fibrosis groups of the hepatitis C patients (P = 0.04 and P = 0.02, respectively). Conclusion: MPV values are more reliable in hepatitis C patients than hepatitis B for predicting the advanced damage in liver histology. This finding might be useful for the detection of early fibrosis and also starting early treatment, which is important in hepatitis C.Publication The relationship of the degree of hepatic fibrosis with hyaluronic acid, type 4 collagen, and procollagen type 3 N-terminal peptide levels in patients with chronic viral hepatitis(Galenos Yayıncılık, 2015-04-01) Irak, Kader; Eminler, Ahmet Tarık; Ayyıldız, Talat; Keskin, Murat; Nak, Selim Giray; Kıyıcı, Murat; Gürel, Selim; Gülten, Macit; Dolar, Enver; Irak, Kader; Eminler, Ahmet Tarık; Ayyıldız, Talat; Keskin, Murat; NAK, SELİM GİRAY; KIYICI, MURAT; GÜREL, SELİM; GÜLTEN, MACİT; DOLAR, MAHMUT ENVER; Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.; 0000-0002-0019-3207; 0000-0003-4526-4352; 0000-0002-3208-6211; DVB-0510-2022; R-8751-2019; CCH-9450-2022; JZY-7001-2024; FQM-3662-2022; AAI-4213-2021; HLH-8209-2023; JGZ-0732-2023; AAG-9177-2021Objective: To investigate the relationship of liver histopathology with the levels of noninvasive markers, namely hyaluronic acid (HA) type 4 collagen and procollagen 3 amino-terminal peptide (P3NP) used for the assessment of hepatic fibrosis in patients with chronic viral hepatitis.Materials and Methods: The study included 80 patients, 56 with chronic hepatitis B (CHB) and 24 with chronic hepatitis C (CHC) who presented to the outpatient clinic at Uludag University Faculty of Medicine, Department of Gastroenterology, and underwent pretreatment liver biopsy between 2008 and 2010. The patients were divided into 2 groups according to the degree of fibrosis: group 1 included patients with grade <= 3 fibrosis (no fibrosis, mild or moderate), group 2 included patients with grade >= 4 fibrosis (severe fibrosis). The association of hepatic fibrosis grade with HA, type 4 collagen, and P3NP was examined.Results: Among the 65 patients in group 1 whose fibrosis grade was confirmed via liver biopsy, 47 (72.3%) had HBV and 18 (27.7%) had HCV, whereas 9 of 15 (60%) in group 2 had HBV and 6 of 15 (40%) had HCV. There was no significant difference in the non-invasive fibrosis markers between the groups (p>0.05). In addition, there was not a significant difference in HA and P3NP levels between the CHB patients in groups 1 and 2 (p>0.05), but the type 4 collagen level was significantly higher in the HBV patients in group 2 (p<0.05). On the other hand, there were no significant differences in HA, type 4 collagen, and P3NP levels, or fibrosis grade between the HC patients (p>0.05).Conclusion: The use of any marker or combination of markers examined in the present study is not a substitute for liver biopsy for assessing hepatic fibrosis. The fibrosis markers examined in the present study could be further examined in research on anti-fibrotic treatment. Future clinical investigations are needed for the evaluation of the value of these tests in diagnosis and monitoring. It should not be forgotten that the basic diagnostic approach is liver biopsy.Publication Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis(Baishideng Publishing Group Inc, 2007-02-14) Yılmaz, Yusuf; Dolar, Enver; Ulukaya, Engin; Akgöz, Semra; Keskin, Murat; Kıyıcı, Murat; Aker, Sibel; Yılmaztepe, Arzu; Gürel, Selim; Gülten, Macit; Nak, Selim Giray; Yılmaz, Yusuf; DOLAR, MAHMUT ENVER; Ulukaya, Engin; GÜREL, SELİM; NAK, SELİM GİRAY; Akgöz, Semra; Keskin, Murat; KIYICI, MURAT; Aker, Sibel; YILMAZTEPE ORAL, ARZU; GÜLTEN, MACİT; Uludağ Üniversitesi/Tıp Fakültesi/Dahiliye Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/İstatistik Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; 0000-0003-4518-5283; 0000-0003-4875-5472; 0000-0003-4526-4352; 0000-0002-3208-6211; 0000-0002-8962-9758; K-6651-2012; AAG-9177-2021; K-5792-2018; EKV-4953-2022; JZY-7001-2024; AAI-4213-2021; EJH-8721-2022; A-5841-2017; HLH-8209-2023; EYR-7166-2022; FQM-3662-2022AIM: To investigate whether serum levels of two soluble forms of extracellular cytokeratin 18 (M30-antigen and M65-antigen) may differentiate nonalcoholic steatohepatitis (NASH) from simple steatosis in patients with nonalcoholic fatty liver disease (NAFLD).METHODS: A total of 83 patients with suspected NAFLD and 49 healthy volunteers were investigated. Patients with suspected NAFLD were classified according to their liver histology into four groups: definitive NASH (n = 45), borderline NASH (n = 24), simple fatty liver (n = 9), and normal tissue (n = 5). Serum levels of caspase-3 generated cytokeratin-18 fragments (M30-antigen) and total cytokeratin-18 (M65-antigen) were determined by ELISA.RESULTS: Levels of M30-antigen and M65-antigen were significantly higher in patients with definitive NASH compared to the other groups. An abnormal value (> 121.60 IU/L) of M30-antigen yielded a 60.0% sensitivity and a 97.4% specificity for the diagnosis of NASH. Sensitivity and specificity of an abnormal M65-antigen level (> 243.82 IU/L) for the diagnosis of NASH were 68.9% and 81.6%, respectively. Among patients with NAFLD, M30-antigen and M65-antigen levels distinguished between advanced fibrosis and early-stage fibrosis with a sensitivity of 64.7% and 70.6%, and a specificity of 77.3% and 71.2%, respectively.CONCLUSION: Serum levels of M30-antigen and M65-antigen may be of clinical usefulness to identify patients with NASH. Further studies are mandatory to better assess the role of these apoptonecrotic biomarkers in NAFLD pathophysiology. (C) 2007 The WJG Press. All rights reserved.Publication Esomeprazole in acute and maintenance treatment of reflux oesophagitis: A multicentre prospective study(Springer, 2008-06-01) Atuğ, Özlen; Giral, Adnan; Kalaycı, Cem; Dolar, Enver; Isıtan, Fahri; Oğuz, Dilek; Övünç, Oya; Özgür, Orhan; DOLAR, MAHMUT ENVER; Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.; AAG-9177-2021Introduction: The aim of this study was to assess the efficacy and safety of esomeprazole 40 mg once daily (q.d.) in healing reflux oesophagitis at 4 and 8 weeks, and the efficacy of esomeprazole 20 mg q.d. for 12 weeks in the maintenance of remission.Methods: A total of 235 patients with endoscopically proven reflux oesophagitis were enrolled in this study, which consisted of two phases (healing and maintenance therapy). Patients who showed complete endoscopic and symptomatic healing at the end of 4 or 8 weeks were switched to maintenance treatment with esomeprazole 20 mg q.d. for 12 weeks. The primary efficacy endpoint was healing of reflux oesophagitis at week 8. Secondary assessments included the proportion of patients with symptomatic relapse in the maintenance phase.Results: At the end of week 8, 88% (95% life-table confidence intervals [CI]: 84%, 92%) of patients were healed endoscopically and 90.6% of the patients were asymptomatic. Patient age, gender and Helicobacter pylori status had no effect on the efficacy of treatment. During the 12-week maintenance treatment phase, symptomatic relapse ratios were 0.5%, 2.2%, and 0%, for the first, second, and third 4-week periods, respectively. The proportions of patients satisfied with treatment were 95% and 99.4% at the end of acute and maintenance treatment, respectively. The most common adverse effects were headache, upper respiratory tract infection and abdominal pain.Conclsions: Esomeprazole is effective in the healing of reflux oesophagitis, the resolution of heartburn, and in maintaining symptomatic remission. The effectiveness of esomeprazole in patients with gastroesophageal reflux disease is not affected by the presence of H. pylori.